C
Claudia S. Moy
Researcher at National Institutes of Health
Publications - 83
Citations - 17716
Claudia S. Moy is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Stroke & Population. The author has an hindex of 46, co-authored 83 publications receiving 15506 citations. Previous affiliations of Claudia S. Moy include Centers for Disease Control and Prevention & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
The Neurology Quality-of-Life Measurement Initiative
David Cella,Cindy J. Nowinski,Amy H. Peterman,David Victorson,Deborah M. Miller,Jin Shei Lai,Claudia S. Moy +6 more
TL;DR: The development and calibration of the banks and scales of the Quality of Life in Neurological Disorders (Neuro-QOL) project are described, with validation efforts in clinical populations and new bank development in health domains not presently included.
Journal ArticleDOI
Carotid revascularization and medical management for asymptomatic carotid stenosis: Protocol of the CREST-2 clinical trials:
Virginia J. Howard,James F. Meschia,Brajesh K. Lal,Tanya N. Turan,Gary S. Roubin,Robert D. Brown,Jenifer H. Voeks,Kevin M. Barrett,Bart M. Demaerschalk,John Huston,Ronald M. Lazar,Wesley S. Moore,Virginia G. Wadley,Seemant Chaturvedi,Claudia S. Moy,Marc I. Chimowitz,George Howard,Thomas G. Brott +17 more
TL;DR: The CREST-2 trial will test whether carotid endarterectomy orCarotid stenting plus contemporary intensive medical therapy is superior to intensive medical Therapy alone in the primary prevention of stroke in patients with high-grade asymptomatic Carotid stenosis.
Journal ArticleDOI
High-dose albumin treatment for acute ischaemic stroke (ALIAS) part 2: a randomised, double-blind, phase 3, placebo-controlled trial
Myron D. Ginsberg,Yuko Y. Palesch,Michael D. Hill,Renee H Martin,Claudia S. Moy,William G. Barsan,Bonnie D. Waldman,Diego Tamariz,Karla J Ryckborst +8 more
TL;DR: The findings show no clinical benefit of 25% albumin in patients with ischaemic stroke; however, they should not discourage further efforts to identify effective strategies to protect theIschaemic brain, especially because of preclinical literature showing convincing proof ofprinciple for this outcome.
Journal ArticleDOI
Insulin-dependent Diabetes Mellitus, Physical Activity, and Death
Claudia S. Moy,Thomas J. Songer,Ronald E. LaPorte,Janice S. Dorman,Andrea M. Kriska,Trevor J. Orchard,Dorothy J. Becker,Allan L. Drash +7 more
TL;DR: Activity is not detrimental with regard to mortality, and may in fact provide a beneficial effect in terms of longevity in diabetes patients, according to a cohort of patients followed as part of the Pittsburgh Insulin-dependent Diabetes Mellitus Morbidity and Mortality Study.
Journal ArticleDOI
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial.
Magdy Selim,Magdy Selim,Lydia D. Foster,Claudia S. Moy,Guohua Xi,Michael D. Hill,Lewis B. Morgenstern,Steven M. Greenberg,Michael L. James,Vineeta Singh,Wayne M. Clark,Casey Norton,Yuko Y. Palesch,Sharon D. Yeatts,Monica Dolan,Erlinda Yeh,Kevin N. Sheth,Kimberly Kunze,Susanne Muehlschlegel,Iryna Nieto,Jan Claassen,Cristina Falo,David Huang,Anne Beckwith,Steven R. Messé,Melissa Yates,Kristine O'Phelan,Andrea Escobar,Kyra J. Becker,Patricia Tanzi,Nicole R. Gonzales,Chad Tremont,Chitra Venkatasubramanian,Rosita Thiessen,Supriya Save,Steven Verrault,Karin Collard,Michael DeGeorgia,Valerie Cwiklinski,Bradford B Thompson,Lesley Wasilewski,Charles M. Andrews,Robert Burfeind,Michel T. Torbey,Mohammad Hamed,Kenneth Butcher,Leka Sivakumar,Nicolaou Varelas,Kathleen Mays-Wilson,Enrique C. Leira,Heena Olalde,Scott Silliman,Rhonda Calhoun,Neha S. Dangayach,Ricardo Renvill,Rishi Malhotra,Kristina Kordesch,Aaron Lord,Thomas Calahan,Romergryko G. Geocadin,Michelle Parish,James L. Frey,Mary Harrigan,Dana Leifer,Ryna Mathias,Michael J. Schneck,Tara Bernier,Sergio Gonzales-Arias,Josette Elysee,George A. Lopez,Josephine Volgi,Robert H. Brown,Sara Jasak,Stephen J. Phillips,Judith Jarrett,Joao Gomes,Moneen McBride,Francois Aldrich,Charlene Aldrich,Joshua Kornbluth,Michelle Bettle,Joshua N. Goldstein,Gregory Tirrell,Qaisar Shaw,Karin Jonczak +84 more
TL;DR: The primary result showed that further study of the efficacy of deferoxamine mesylate with anticipation that the drug would significantly improve the chance of good clinical outcome would be futile and the drug merits investigation in a phase 3 trial.